Skip to main content

Table 3 Patient characteristics based on baseline NLR

From: Clinical utility of blood neutrophil-lymphocyte ratio in Japanese COPD patients

  NLR < 2.7 NLR ≥ 2.7 p-value
Number 199 66  
Gender, female, n (%) 14 (7.0) 3 (4.6) 0.474
Age, years 71.6 ± 8.1 74.0 ± 7.1 0.037
Smoking Index, pack-years 53.7 ± 28.8 59.9 ± 33.8 0.159
Current smokers, n (%) 21 (10.7) 4 (6.1) 0.270
BMI, kg/m2 23.2 ± 2.9 22.0 ± 3.4 0.005
FEV1/FVC, (%) 53.8 ± 11.8 48.9 ± 13.3 0.005
% FEV1, (%) 66.5 ± 20.4 55.8 ± 21.3 0.0003
LAA%, (%) 11.3 (5.0–23.3) 18.4 (6.4–28.7) 0.093
WA%, (%) 52.4 (47.4–57.7) 54.9 (46.4–59.8) 0.416
Baseline CAT score 11.5 ± 8.0 13.9 ± 7.7 0.039
SGRQ total score 24.8 ± 18.0 36.2 ± 19.1 < 0.001
LAMA, n (%) 120 (60.3) 44 (66.7) 0.356
LABA, n (%) 94 (47.2) 40 (60.6) 0.060
ICS, n (%) 63 (31.7) 28 (42.4) 0.111
Dose of ICSa, μg/day, median 500 500 0.980
Eosinophil, (%) 3.6 ± 2.6 2.9 ± 2.4 0.080
Eosinophil, n 209 ± 149 188 ± 153 0.318
  1. Data are shown as mean ± SD and median (interquartile range)
  2. COPD chronic obstructive pulmonary disease, NLR Neutrophil-to-Lymphocyte ratio, BMI body mass index, FEV 1 forced expiratory volume in one second, FVC forced vital capacity, % FEV 1 ratio of predicted FEV1, LAA% ratio of low attenuation area, WA% ratio of airway wall area, CAT COPD assessment test, SGRQ St. George’s Respiratory Questionnaire, LAMA long-acting muscarinic antagonist, LABA long-acting β2 agonist, ICS inhaled corticosteroids, CRP C-reactive protein, SAA serum amyloid A
  3. aDose of inhaled corticosteroid is shown as fluticasone propionate equivalent